HPV-driven oropharyngeal squamous cell cancer in Croatia — Demography and survival

Ksenija Božinović, Ivan Sabol, Zoran Rakušić, Antonia Jakovčević, Mario Šekerija, Juraj Lukinović, Drago Prgomet, Magdalena Grce

1 Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia, 2 Department of Radiation Oncology, Oncology Clinics, University Hospital Center Zagreb, Zagreb, Croatia, 3 School of Medicine, University of Zagreb, Zagreb, Croatia, 4 Clinical Department of Pathology and Cytology, University Hospital Center Zagreb, Zagreb, Croatia, 5 Croatian National Cancer Registry, Croatian Institute of Public Health, Zagreb, Croatia, 6 School of Medicine, Andrija Štampar School of Public Health, University of Zagreb, Zagreb, Croatia, 7 Clinic for Ear, Nose and Throat Diseases and Head and Neck Surgeries, University Hospital Center Zagreb, Zagreb, Croatia

* ivan.sabol@irb.hr (IS); grce@irb.hr (MG)

Abstract

Objectives

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide. Main HNSCC risk factors are tobacco, alcohol, and high-risk human papillomavirus (HPV). HPV+ oropharyngeal squamous cell cancer (OPSCC) usually have different etiology, increasing incidence and often show an improved survival when compared to HPV-negative cases. The objective of the current study was to retrospectively examine the influence of HPV on the survival of OPSCC patients in a non-Western population setting.

Materials and methods

We determined the presence of HPV DNA and/or RNA in 99 formalin-fixed paraffin embedded (FFPE) tissue samples of OPSCC patients treated between 2002 and 2015. Patients were compared based on laboratory, demographic, clinical, lifestyle characteristics and survival.

Results

HPV RNA was found in 29.3% cases. However, groups based on HPV data (either RNA, DNA or retrospectively collected p16 staining) did not show significant differences. Overall, 5-year survival was 30% with minimal influence of the HPV positivity.

Conclusions

The HPV influence on survival of OPSCC patients is not identical between populations probably due to other factors overshadowing the HPV effect. This should be taken into account when treatment or policy decisions are made in each particular setting.
Introduction

Head-and-neck cancer (HNC) is a group of malignancies that most commonly arise from the upper aerodigestive tract mucosa or lining of the head-and-neck regions [1]. It is the sixth most common malignancy worldwide. Most HNCs (95%) develop from squamous cell epithelia and are further characterized according to their primary site of origin. Most common sites are oral cavity, oropharynx, pharynx, larynx, and sinonasal tract [2]. Globally, head-and-neck squamous cell carcinoma (HNSCC) accounts for approximately 550,000 cases annually [3] and in Croatia, there were estimated 750 cases in 2014 [4].

The main risk factors in general for developing HNSCC are tobacco, alcohol use and the high-risk human papillomavirus (HPV) presence, with HPV-16 being found in majority of HPV associated HNSCC [5]. High-risk HPV is capable of transforming infected cells into cancerous ones by expressing oncoproteins E6 and E7, which bind, among others, to two of the most important tumor suppressor genes, p53 and pRB, respectively [5]. Previous studies have indicated that HNSCC, while very heterogeneous can be broadly divided into two groups: HPV positive (HPV+) and HPV negative (HPV–). Indeed, HPV is responsible for 30–50% HNSCC, with an increasing trend [5], found initially in the younger population of developed countries, although recent evidence suggests that HPV+ OPSCC is also increasing in older patients [6–8]. HPV+ HNSCC are often of oropharyngeal (OP) origin, with better prognosis and rare p53 mutations, usually with low levels of tobacco and alcohol use [5,9–11]. On the other hand, HPV–tumors are usually found in the elderly population with worse prognosis, without preferable origin, with frequent p53 mutations and having long history of tobacco and alcohol use. It is known that the incidence of HPV–HNSCC in the United States has been declining, presumably due to a reduced prevalence of tobacco smoking [12]. Over the past few decades, however, there has been a rise in HPV+ OPSCC [5,12–14]. In Croatia the trend between 1988 and 2008 was showing decreasing overall incidence of HNSCC [15], with more recent data corroborating the trend [4]. The proportion of HPV associated OPSCC is now approximately 70% in the developing countries, which is a substantial increase from previous rates [5,16]. Even though these two groups of HNSCC are etiologically different, the treatment remains the same [17,18]. However, there are indications that the treatment could be optimized for each group of patients, at least for HPV+ OPSCC patients [11,19]. Therefore, it is crucial to get a better understanding of the disease and get detailed information on patients including socio-epidemiological, clinical, biological and histopathological data.

In Croatia, only clinical guidelines for the treatment of laryngeal cancer currently exist, which is only a subset of HNSCC, accounting for ~33% of HNSCC cases in the country, while there are no guidelines for the treatment of cancers arising at other head-and-neck sites [15]. As HPV involvement seems to drive the increase of OPSCC incidence in developed countries, establishing guidelines for this cancer type could be of a future benefit to patients, but the baseline data for such guidelines are scarce. Thus, in this study, we assessed archival formalin-fixed paraffin embedded (FFPE) tissue of OPSCC patients for HPV presence (DNA) and activity (mRNA) to determine differences in patient characteristics. Furthermore, medical records together with Croatian National Cancer Registry data were evaluated to determine the influence of HPV on survival. The study objective was to gain a better understanding of OPSCC in Croatian and similar non-Western populations.

Materials and methods

Patient samples

For this study, we collected a subset of available FFPE tumor tissue from 104 OPSCC patients treated at the University Hospital Center Zagreb between 2002 and 2015. According to the
International Classification of Disease (ICD-10), tumors included tonsils (C09), base of tongue (C01), soft palate (C05.1), lateral wall (C10.2) and posterior wall of oropharynx (C10.3). One patient had unspecified oropharynx tumor localization. Upon medical records reexamination, five cases were excluded as the tumor originated from supraglotis/hypopharynx, thus 99 cases were retained for analysis. The study was approved by the Bioethical Board of the Ruder Bošković Institute (BEP-3748/2-2014) and the Ethical Board of the University Hospital Center Zagreb (8.1-14/47-2, 02/21-JG). Since the study was retrospective and performed on anonymized data from often deceased patients, the Ethical boards waived the necessity of obtaining additional informed consent. Medical records and patient’s vital status, including previous p16 staining where available, were obtained from the hospital information system and the Croatian National Cancer Registry [4] and contained relevant data collected during the establishment of the initial diagnosis including pathological assessment. Original patient management treatment decisions were not based upon HPV DNA or RNA testing but were made according to tumor stage and overall patient state.

Data from the National Cancer Registry indicates that in the same period there were approximately 1600 OPSCC patients diagnosed throughout Croatia with the same diagnosis codes as used in the manuscript. However, of this number almost 500 were reported to the Registry as C10.9 oropharynx, unspecified, which are underrepresented in our analyzed tissues. The University Hospital Center Zagreb treated 403 oropharyngeal cancer patients during this period. Thus, our sample represents approximately 7% of cancer patients in Croatia and approximately 25% of patients treated at the hospital.

Malignancies were staged according to the 7th Edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) TNM Classification of Malignant tumors [20]. The pathologic classification was used and supplemented with the clinical classification if missing. For the survival analyses, both 7th and 8th AJCC Edition staging guidelines [20,21] have been used and compared. Patient survival time in months was calculated from the date of earliest diagnosis to registered time of death (all cause) or December 31st, 2017.

**Nucleic acid isolation**

Approximately 5–7 10 µm serial sections of each tissue block were obtained for DNA and another 5–7 sections for RNA isolation. Precautions were taken to avoid sample cross-contamination, including change of knife and meticulous cleaning of the microtome for each new block as well as discarding top layers of each block that could potentially have been contaminated during storage. DNA was isolated with a NucleoSpin Tissue kit (Machery-Nagel), while RNeasy FFPE Kit (Qiagen) was used for total RNA isolation of HPV+ samples. Isolation procedures were performed according to the respective manufacturer’s protocol. Extracted DNA and RNA were quantified using NanoPhotometer (Implen, Germany).

**HPV DNA detection**

Extracted DNA adequacy was further confirmed by PCR amplification of beta-actin gene (~99 bp) [22]. HPV DNA detection was performed using short primers suitable for FFPE tissue analysis, GP5/6 (~142bp amplicon) and SPF-10 (~65bp amplicon) previously described [23,24]. CaSki cell line DNA containing HPV-16 was used as positive control, while negative control reactions contained all reagents except DNA. All standard precautions for avoiding cross contamination were followed and reactions were prepared within a UV decontaminated laminar flow hood. PCR products (10 µl) were visualized after 3% agarose gel electrophoresis. A sample was considered as HPV DNA positive if consensus primers, either GP or SPF directed PCR was
positive and the results valid if beta-actin directed PCR (internal control) was successful. HPV specific genotyping was not performed due to DNA degradation in FFPE samples.

**E6/E6' I mRNA expression analyses**

All HPV DNA positive samples were selected for RNA isolation and HPV-16 E6 mRNA detection. RNAse-free DNase digestion was performed to further limit DNA contamination. Briefly, 1 μg of RNA was reverse transcribed using QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturer’s protocol. Most abundant splice variant of the E6 open reading frame (E6’I) was detected by PCR [25] and the amplicons (~86 bp) visualized by a 3% agarose electrophoresis. Suitability of cDNA for amplification was confirmed by beta-actin PCR (~99 bp). CaSki cell line cDNA served as positive control, while negative control contained all reagents except cDNA.

**Immunohistochemistry**

The p16 data was obtained from medical records of staining done by the CINtec p16INK4a Histology Kit (mtm laboratories, Heidelberg, Germany) according to the manufacturer instructions [26]. The staining was evaluated by the same pathologist (AJ) for all patients. The overexpressed p16 (≥70%) in tumour cells was considered as positive.

**Statistical analyses**

Based on HPV DNA and RNA testing results, samples were grouped in three distinct groups: HPV DNA/RNA negative), HPV DNA positive and HPV RNA positive. Statistical analyses were performed using R (v3.4.2) and MedCalc (v11.4 MedCalc Software, Ostend, Belgium). Patient’s characteristics for specific variables (including gender, tumor localization, grade, TNM and therapy) were compared between the groups using Test of Independence/Chi-Square and correlation. Age at diagnosis was analyzed using T-test. For statistical purposes, missing data was recoded as “Unknown” but retained to minimize possible selection bias. Survival data was assessed in MedCalc using Kaplan-Meier analyses from which all non-primary tumors (n = 8) and patients with unavailable survival data (n = 10) were excluded. When assessing tumor staging, patients were grouped to reduce the number of subgroups: for T classification “1–2” and “2–3” groups were considered. For N classification, “0–1” and “2–3” groups were made, while for tumor stages “I-II” and “III-IV” groups were considered irrespective of staging edition. Patients self-reporting weekly or more common strong spirit use or daily other alcohol use were grouped as heavy drinkers, while patients with self-reported occasional or limited alcohol use were grouped as occasional drinkers. Influence of individual variables on survival were modeled with Cox proportional hazards regression in univariate analysis for age, gender, HPV DNA positivity, HPV RNA positivity, p16 positivity, T classification, N classification, stage, grade, smoking history and drinking history. Several multivariate Cox proportional hazards regression models were created from selected significant or relevant variables (T/N classification) and HPV groups. Several models were created from all entered variables without removal of non-significant variables to enable the comparison of individual variable effects. However, the models including “Unknown” groups couldn’t be solved so for multivariate analysis, samples with “Unknown” factors were removed. P values less than 0.05 were considered significant.

**Results**

From a total of 99 OPSCC patients, 59 (59.6%) were HPV DNA negative and 40 (40.4%) HPV DNA positive, of which 11 (27.5%) were RNA negative, and 29 (72.5%) RNA positive.
Statistical analysis was done on those 3 subgroups: HPV DNA/RNA negative (N = 59), DNA positive/RNA negative (N = 11), and DNA/RNA positive (N = 29). In addition, the tests were also performed on the whole HPV DNA positive subgroup, including both RNA negative and RNA positive samples (N = 40), but no additional statistical significance was found. Patient’s characteristics are presented in Table 1. Male patients were predominant in all groups, and account for 82.8% cases. Tonsil and base of tongue were the most common subsites, together accounting for more than 86% of cases. There were no statistically significant differences between the HPV groups in terms of age at the time of diagnosis (Fig 1) or gender. There were 14% never smokers and 13% never drinkers without significant differences between groups. There was no correlation between HPV and p16 results with Pearson’s correlation coefficient r = 0.14 for comparison with HPV RNA. The p16 positive staining was weakly statistically associated with patient’s older age (t-test, P = 0.042) and with cancer higher grade (Mann-Whitney, P = 0.017).

Table 1. Characteristics of the study population.

| Variable            | HPV DNA and RNA positive (N = 29) | HPV DNA positive and RNA negative (n = 11) | HPV negative (n = 59) | Total (n = 99) * |
|---------------------|----------------------------------|------------------------------------------|----------------------|------------------|
| Gender              |                                  |                                          |                      |                  |
| Male                | 22 (26.8%)                       | 10 (12.2%)                               | 50 (60.9%)           | 82 (82.8%)       |
| Female              | 7 (41.2%)                        | 1 (5.9%)                                 | 9 (52.9%)            | 17 (17.2%)       |
| Tumor site          |                                  |                                          |                      |                  |
| Tonsil              | 17 (32.1%)                       | 6 (11.3%)                                | 30 (56.6%)           | 53 (53.5%)       |
| Base of tongue      | 10 (30.3%)                       | 5 (15.2%)                                | 18 (54.6%)           | 33 (33.3%)       |
| Soft palate         | 0 (0%)                           | 0 (0%)                                   | 7 (100%)             | 7 (7.1%)         |
| Lateral pharyngeal wall | 2 (40%)          | 0 (0%)                                   | 3 (60%)              | 5 (5.1%)         |
| Oropharynx (unspecified) | 0 (0%)                | 0 (0%)                                   | 1 (100%)             | 1 (1.0%)         |
| Age group           |                                  |                                          |                      |                  |
| <45                 | 2 (33.3%)                        | 0 (0%)                                   | 4 (66.7%)            | 6 (6.1%)         |
| 45–64               | 17 (27.9%)                       | 9 (14.8%)                                | 35 (57.4%)           | 61 (61.6%)       |
| 65+                 | 10 (31.3%)                       | 2 (6.3%)                                 | 20 (62.5%)           | 32 (32.3%)       |
| Median age          | 60                               | 59                                       | 60                   | 60               |
| Smoking             |                                  |                                          |                      |                  |
| Active              | 4 (18.2%)                        | 4 (18.2%)                                | 14 (63.6%)           | 22 (22.2%)       |
| Former              | 2 (20%)                          | 0 (0%)                                   | 8 (80%)              | 10 (10.1%)       |
| Does not smoke      | 6 (42.9%)                        | 2 (14.3%)                                | 6 (42.9%)            | 14 (14.1%)       |
| Unknown             | 17 (32.1%)                       | 5 (9.4%)                                 | 31 (58.5%)           | 53 (53.5%)       |
| Drinking            |                                  |                                          |                      |                  |
| Heavy               | 1 (12.5%)                        | 1 (12.5%)                                | 6 (75%)              | 8 (8.1%)         |
| Occasional          | 5 (20%)                          | 4 (16%)                                  | 16 (64%)             | 25 (25.3%)       |
| Does not drink      | 6 (46.6%)                        | 1 (7.7%)                                 | 6 (46.2%)            | 13 (13.1%)       |
| Unknown             | 17 (32.1%)                       | 5 (9.4%)                                 | 31 (58.5%)           | 53 (53.5%)       |

*total column percentages are calculated against the grand total

https://doi.org/10.1371/journal.pone.0211577.t001
Clinical parameters are presented in Table 2; the majority of all patients with available data were diagnosed with stage III or worse cancer (76.6%) according to the 7th edition AJCC guidelines [20], and there was no significant difference between groups. However, according to the 8th edition AJCC guidelines [21], the majority of RNA positive tumors were staged as early and in this case the difference vs HPV–tumor group was significant (Chi-square test, $P < 0.0001$). Only 10% patients, for which data were available, were treated non-surgically. Palliative therapy only was administered for 5 patients.

For survival analyses, 2 HPV RNA positive and 6 HPV RNA negative samples have been excluded, due to samples originating from recurrent and not primary tumors. In addition, for 10 patients, follow-up or survival data couldn’t be obtained, and have been excluded. Thus, all-cause mortality outcomes could be assessed for a total of 81 patients. Median follow-up (up to December 31st, 2017) was 23.9 months. The overall survival at 5-years was 30.9%. Kaplan-Meier survival curves for patient characteristics, clinical parameters, therapy and different staging approaches are presented in Figs 2, 3 and 4, respectively. Combined risk level, taking into account different patient aspects was aggregated and calculated as suggested by Ang et al [27]. The original method included the grouping by HPV status, smoking and T and N stages for HPV+ and HPV–cases, respectively. However, smoking was disregarded to retain more cases, as smoking information was not available for all patients. Moreover, low and intermediate groups were combined as there were only 5 patients satisfying “low risk” criteria based on the HPV RNA presence (Fig 4).

Patient characteristics (Fig 2) were not significantly (logrank test of Kaplan Myer survival curves) affecting survival even though female gender, younger age and no history of smoking/drinking were somewhat beneficial. Of clinical parameters (Fig 3), only T ($P = 0.041$) and N ($P = 0.021$) classification significantly affected the overall outcome. On the other hand, HPV + and HPV–patients, regardless of the method of HPV detection (DNA, RNA or p16), had very similar survival. The effect of therapy on survival (Fig 4) was also significant ($P = 0.019$). In addition, both 7th ($P = 0.017$) and 8th ($P = 0.001$) editions of AJCC guidelines statistically significantly affected survival. The analyses based on combined risk level (HPV status and T/N
Table 2. Patient clinical characteristics.

| Variable | HPV DNA and RNA positive (N = 29) | HPV DNA positive and RNA negative (n = 11) | HPV negative (n = 59) | Total b (n = 99) |
|----------|-----------------------------------|------------------------------------------|---------------------|----------------|
| T        |                                   |                                          |                     |                |
| 1        | 4 (13.8%)                         | 2 (18.2%)                                | 5 (8.5%)            | 11 (11.1%)     |
| 2        | 6 (20.7%)                         | 4 (36.4%)                                | 19 (32.2%)          | 29 (29.3%)     |
| 3        | 6 (20.7%)                         | 2 (18.2%)                                | 8 (13.6%)           | 16 (16.2%)     |
| 4        | 3 (10.3%)                         | 1 (9.1%)                                 | 13 (22.0%)          | 17 (17.2%)     |
| Unknown  | 10 (34.5%)                        | 2 (18.2%)                                | 14 (23.7%)          | 26 (26.3%)     |
| N        |                                   |                                          |                     |                |
| 0        | 3 (10.3%)                         | 3 (27.3%)                                | 18 (30.5%)          | 24 (24.2%)     |
| 1        | 5 (17.2%)                         | 3 (27.3%)                                | 4 (6.8%)            | 12 (12.1%)     |
| 2        | 11 (37.9%)                        | 3 (27.3%)                                | 18 (30.5%)          | 32 (32.3%)     |
| 3        | 0 (0%)                            | 0 (0%)                                   | 5 (8.5%)            | 5 (5.1%)       |
| Unknown  | 10 (34.5%)                        | 2 (18.2%)                                | 14 (23.7%)          | 26 (26.3%)     |

7th edition staging guidelines

| Variable | Early | I | II | Late | III | IVa | IVb | IVc | Unknown |
|----------|-------|---|----|------|-----|-----|-----|-----|---------|
| T        | 3 (10.3%) | 1 (3.5%) | 2 (6.9%) | 16 (55.2%) | 6 (20.7%) | 10 (34.5%) | 0 (0%) | 10 (34.5%) |
| N        | 3 (10.3%) | 1 (9.1%) | 1 (9.1%) | 7 (63.6%) | 3 (27.3%) | 2 (18.2%) | 0 (0%) | 2 (18.2%) |
| Grade 1  | 9 (31.0%) | 1 (9.1%) | 1 (9.1%) | 3 (10.3%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 10 (34.5%) |
| Grade 2  | 7 (24.1%) | 1 (9.1%) | 1 (9.1%) | 7 (63.6%) | 3 (27.3%) | 2 (18.2%) | 0 (0%) | 2 (18.2%) |
| Grade 3  | 9 (31.0%) | 1 (9.1%) | 1 (9.1%) | 7 (63.6%) | 3 (27.3%) | 2 (18.2%) | 0 (0%) | 2 (18.2%) |
| 8th edition staging guidelines

| Variable | Early | I | II | Late | III | IVa | IVb | IVc | Unknown |
|----------|-------|---|----|------|-----|-----|-----|-----|---------|
| T        | 16 (55.2%) | 7 (24.1%) | 9 (31.0%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) | 10 (34.5%) |
| N        | 16 (55.2%) | 7 (24.1%) | 9 (31.0%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) | 2 (18.2%) |
| Grade 1  | 16 (55.2%) | 7 (24.1%) | 9 (31.0%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) | 10 (34.5%) |
| Grade 2  | 16 (55.2%) | 7 (24.1%) | 9 (31.0%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) | 2 (18.2%) |
| Grade 3  | 16 (55.2%) | 7 (24.1%) | 9 (31.0%) | 3 (10.3%) | 3 (10.3%) | 0 (0%) | 0 (0%) | 2 (18.2%) |

| Therapy c | Surgical | Surgery | Surgery + RT | Surgery + CRT | Non-surgical | Palliative | Unknown |
|-----------|----------|---------|--------------|--------------|-------------|------------|---------|
| T        | 18 (62.1%) | 11 (37.9%) | 4 (13.8%) | 3 (10.3%) | 1 (3.5%) | 2 (6.9%) | 8 (27.6%) |
| N        | 8 (72.7%) | 2 (18.2%) | 5 (45.5%) | 1 (9.1%) | 1 (9.1%) | 0 (0%) | 2 (18.2%) |
| Grade 1  | 18 (62.1%) | 11 (37.9%) | 4 (13.8%) | 3 (10.3%) | 1 (3.5%) | 2 (6.9%) | 8 (27.6%) |
| Grade 2  | 18 (62.1%) | 11 (37.9%) | 4 (13.8%) | 3 (10.3%) | 1 (3.5%) | 2 (6.9%) | 8 (27.6%) |
| Grade 3  | 18 (62.1%) | 11 (37.9%) | 4 (13.8%) | 3 (10.3%) | 1 (3.5%) | 2 (6.9%) | 8 (27.6%) |
| p16 Positive | 7 (24.1%) | 2 (18.2%) | 7 (63.6%) | 3 (10.3%) | 2 (18.2%) | 10 (34.5%) | 17 (28.8%) |

a 26 patients had missing data for T/N classification of which 4 had recorded distant metastases and were thus classified as stage IVc

b total percentages are calculated against grand total

c RT- radio therapy, CRT—chemo and/or radiotherapy, non-surgical—any combination of chemo/radio therapy

https://doi.org/10.1371/journal.pone.0211577.t002
Fig 2. Overall survival of OPSCC patients based on the gender, age group at the time of diagnosis, smoking history and alcohol use.

https://doi.org/10.1371/journal.pone.0211577.g002

Fig 3. Overall survival of OPSCC patients based on HPV positivity, p16 data, and T and N classification.

https://doi.org/10.1371/journal.pone.0211577.g003
stage) also significantly separated patients’ survival \((P = 0.001)\). Cox proportional hazards regression in univariate and multivariate analysis are presented in Tables 3 and 4.

**Discussion**

In this study, we performed HPV DNA and RNA analysis of oropharyngeal cancer patients treated within a 15-year period. The overall results indicate that 29.3% of cancer cases had active HPV E6 mRNA transcription and were thus likely HPV driven. The HPV DNA positivity, on the other hand, was shown in 40.4% patients, which is comparable with previous reports \([13,16]\). Previous studies \([11,28–30]\) have already concluded that HPV DNA presence is not always sufficient to attribute cancer to HPV and that mRNA or combination of assays should be used. Unexpectedly, the correlation between p16 and HPV data was low with correlation coefficients \(r = -0.108\) for comparison with HPV DNA and \(r = 0.146\) for comparison with RNA suggesting that p16 is not a suitable replacement for HPV testing in the current setting. Some other studies have also shown that p16 testing might not be an accurate biomarker for oropharyngeal cancers, since the presence of p16 has been detected in HPV–HNSCC \([31]\). However, literature also suggests that p16 positive, but HPV negative HNSCC, share some common characteristics, like favorable prognosis, with HPV+ HNSCC \([5,30,31]\). However, in our study there were also several HPV+ yet p16 negative tumors that negatively affected the correlation. Such samples were also seen in the study of Jordan et al. \([32]\). However, recent Cancer Genome Atlas project analysis \([33]\) indicated that CDKN2A gene (encoding p16 protein) is often deleted or mutated in smoking related HNSCC cancers. Such deletions would preclude p16 overexpression even if HPV is transcriptionally active.
This study encompass samples mostly from male patients with cancer in the oropharyngeal region, particularly base of tongue and tonsil, which is consistent with previous reports [13,34]. Those two regions also had the most HPV+ cases, which is in line with the literature.

| Variable   | Factor* | N   | Relative risk | 95% confidence interval | P     | Overall model significance |
|------------|---------|-----|---------------|-------------------------|-------|---------------------------|
| Gender     | F       | 16  | 1             |                         |       | P = 0.207                 |
|            | M       | 65  | 1.5           | 0.7 to 2.9              | 0.229 |                           |
| Age        | continuous | 81  | 1             | 0.9 to 1.1              | 0.063 | P = 0.062                 |
|            | <45     | 6   |               |                         |       | P = 0.127                 |
|            | 45–64   | 51  | 2.8           | 0.9 to 9.2              | 0.081 |                           |
|            | 65+     | 24  | 2.6           | 0.8 to 8.9              | 0.126 |                           |
| T          | 1–2     | 34  | 1             |                         |       | P = 0.038                 |
|            | 3–4     | 29  | 1.9           | 1.1 to 3.5              | 0.017 |                           |
|            | Unknown | 18  | 1.8           | 0.9 to 3.4              | 0.079 |                           |
| N          | 0–1     | 30  | 1             |                         |       | P = 0.006                 |
|            | 2–3     | 33  | 2.4           | 1.4 to 4.3              | 0.003 |                           |
|            | Unknown | 18  | 2.1           | 1.1 to 3.9              | 0.037 |                           |
| Stage 7th  | I-II    | 17  | 1             |                         |       | P = 0.009                 |
|            | III-IV  | 50  | 2.6           | 1.3 to 5.2              | 0.006 |                           |
|            | Unknown | 14  | 2.6           | 1.1 to 6.1              | 0.031 |                           |
| Stage 8th  | I-II    | 26  | 1             |                         |       | P = 0.001                 |
|            | III-IV  | 41  | 2.9           | 1.6 to 5.4              | 0.001 |                           |
|            | Unknown | 14  | 2.4           | 1.1 to 5.1              | 0.029 |                           |
| Grade      | 1       | 19  | 1             |                         |       | P = 0.876                 |
|            | 2       | 29  | 1.1           | 0.6 to 2.3              | 0.619 |                           |
|            | 3       | 31  | 1.1           | 0.6 to 2.2              | 0.711 |                           |
|            | Unknown | 2   | 2.4           | 0.5 to 10.7             | 0.246 |                           |
| HPV overall| no HPV  | 49  | 1             |                         |       | P = 0.893                 |
|            | inactive HPV | 11  | 0.9         | 0.4 to 1.8             | 0.763 |                           |
|            | active HPV   | 21  | 1.1           | 0.6 to 1.9             | 0.776 |                           |
| HPV DNA    | no HPV  | 49  | 1             |                         |       | P = 0.964                 |
|            | HPV DNA+   | 32  | 1.0           | 0.6 to 1.7             | 0.965 |                           |
| HPV RNA    | no HPV  | 60  | 1             |                         |       | P = 0.714                 |
|            | HPV RNA+   | 21  | 1.1           | 0.6 to 1.9             | 0.712 |                           |
| p16        | p16 negative | 36  | 1             |                         |       | P = 0.569                 |
|            | p16 +     | 22  | 1.2           | 0.7 to 2.0             | 0.603 |                           |
|            | Unknown   | 23  | 0.8           | 0.4 to 1.5             | 0.510 |                           |
| Alcohol    | No alcohol | 11  | 1             |                         |       | P = 0.075                 |
|            | Occasional use | 18  | 2.3         | 0.8 to 6.4             | 0.103 |                           |
|            | Heavy use  | 8   | 4.0           | 1.3 to 12.3            | 0.015 |                           |
|            | Unknown   | 44  | 2.5           | 0.9 to 6.3             | 0.059 |                           |
| Smoking    | No smoking  | 8   | 1             |                         |       | P = 0.279                 |
|            | Former     | 9   | 2.7           | 0.7 to 10.3            | 0.138 |                           |
|            | Current     | 20  | 2.7           | 0.8 to 9.1             | 0.115 |                           |
|            | Unknown     | 44  | 2.7           | 0.8 to 8.7             | 0.099 |                           |

*Factors reaching statistical significance are highlighted by bold font

https://doi.org/10.1371/journal.pone.0211577.t003
and cancers at those particular sites are the most responsible for the rising incidence of HNSCC in many Western countries [12,36,37]. Surprisingly, there were no significant differences in patient or clinical parameters between groups based on HPV RNA or only DNA or even p16 results. The overall 5-year survival was relatively low (30.9%), however, this was influenced by the lack of disease specific mortality data, which allows the calculation based only on all-cause mortality for the majority of patients. The use of all-cause mortality might also be masking the effects of other variables, which, with the exception of T and N stages ($P = 0.041$ and $P = 0.022$, respectively), failed to adequately stratify patient risk of death on Kaplan-Meyer analysis. However, the combined risk stratification as proposed by Ang et al [27] originally combining HPV, smoking (not included in our calculation) and TNM stage almost perfectly classified patients in low/intermediate and high risk of death groups (Fig 4; $P = 0.001$). Similar results were obtained on univariate and multivariate Cox proportional hazards regression (Tables 3 and 4). Namely, only T and N classifications (and staging based on this variables) significantly affected survival with the N classification significant in both univariate and multivariate models. However, HPV did not confer significant survival benefit in either test.

The lack of impact of HPV or even p16 on survival was surprising; however, several factors could be responsible. One of the major influences that could mask any positive HPV/p16 effects on survival is smoking and drinking history. Only 14% of patients never smoked and 13% never consumed alcohol with the majority still being an active smoker and at least moderate drinker (Table 1). Smoking is still a significant problem in Croatia [38], with almost no change in smoking prevalence seen for males in the 1994–2005 period with a slight decrease from 34.1% to 33.8%. The more recent World Health Organization (WHO) report on smoking prevalence [39] estimates an even greater male smoking prevalence in Croatia for year 2015 at 37.9% with the similar rate, around 24% for UK or USA. This, together with previous studies that have shown that smoking can have the greatest effect on survival and even outweigh HPV effect [40,41], most probably explains our findings. The hazardous effect of smoking on cancer risk was shown for both HPV+ and HPV–HNSCC [42] even at low doses [43]. Furthermore, the strong influence of smoking on cancer in Croatia is also demonstrated in a recent review

| Variable | Factor* | Multivariate model 1 (n = 63) overall model significance | Multivariate model 2 (n = 35) overall model significance |
|----------|---------|----------------------------------------------------------|----------------------------------------------------------|
|          |         | Relative risk | 95% confidence interval | $P$ | Relative risk | 95% confidence interval | $P$ |
| T        | 1–2     | 1             |                             | \ | 1             |                             | \ |
|          | 3–4     | 1.3           | 0.6 to 2.5 | 0.485 | 1.9           | 0.7 to 5.2 | 0.241 |
| N        | 0–1     | 1             |                             | \ | 1             |                             | \ |
|          | 2–3     | 3.3           | 1.5 to 7.1 | 0.003 | 4.6           | 1.2 to 17.0 | 0.023 |
| HPV overall |         |               |                             | \ | 1             |                             | \ |
|          | no HPV  |               |                             | \ | 1             |                             | \ |
|          | inactive HPV | 2.3         | 1.0 to 5.0 | 0.043 | 3.3           | 0.9 to 11.5 | 0.069 |
|          | active HPV | 0.5           | 0.2 to 1.1 | 0.091 | 1.0           | 0.3 to 3.5 | 0.967 |
| Alcohol  | No alcohol | not included in model |                             | \ | 1             |                             | \ |
|          | Occasional use |                 |                             | \ | 1.4843 | 0.4 to 5.6 | 0.560 |
|          | Heavy use |                 |                             | \ | 2.9149 | 0.7 to 13.2 | 0.166 |
| Smoking  | No smoking | not included in model |                             | \ | 1             |                             | \ |
|          | Former |                 |                             | \ | 1.7463 | 0.3 to 9.1 | 0.510 |
|          | Current |                 |                             | \ | 0.8471 | 0.2 to 4.4 | 0.845 |

*Factors reaching statistical significance are highlighted by bold font

https://doi.org/10.1371/journal.pone.0211577.t004

[35] and cancers at those particular sites are the most responsible for the rising incidence of HNSCC in many Western countries [12,36,37].
of lung cancer [44]. Therein, Croatia was among 20 countries with the highest incidence of lung cancer in the world. Thus, Croatian patients are yet to benefit from smoking cessation programs and past smoking history most likely influenced development of associated cancer types. It was moderately surprising that smoking was not significantly affecting survival on Cox regression analysis; however, it is likely that patients self-reported less smoking than they actually did due to the recent social stigma associated with smoking and antismoking campaign. The multivariate models also suffer from lack of data since only 35 patients had complete information for analysis. Similarly, alcohol drinking is known to increase cancer risk [45] and it is prominent in the Croatian population. The WHO report on alcohol consumption [46] put Croatia among the top countries according to age standardized alcohol-attributable malignant neoplasm death rates in 2016. Interestingly the univariate model indicated that heavy drinking (and/or strong spirits use) significantly decreased survival (Table 3) indicating that alcohol might represent even a higher health concern than smoking in Croatia.

Another factor potentially influencing our findings is that, surprisingly, there were no significant differences between groups with regards to age at diagnosis in our study population, which might also hint at a more classical etiology. Previous studies have shown that HPV + HNSCC primarily affects younger patients with higher socio-economic status and this particular group is the underlying cause for increasing incidence of HNSCC [5,34,47–49]. It appears that in Croatia, and possibly elsewhere, societal and life style changes are lagging behind more developed countries and not enough time has elapsed to shift the importance of risk factors in HNSCC development from classical smoking and drinking to the new HPV related risks. There appears to be no significant shift in incidence (particularly in younger patients) or survival usually associated with HPV positivity. Interestingly, the study by Nygard et al [49] showed that in Norway, there was a period (1981–1995) in which the survival of HPV + HNSCC was even worse than the HPV–HNSCC. However, in more recent years (1996–2007) there was a dramatic shift in the survival of HPV+ patients. The median age of diagnosis decreased from 63.2 to 59.8 years for HPV+ but remained unchanged at 66 for HPV–patients. In our study, there was no observable difference in age at diagnosis between patient groups, and there were no survival differences, thus, making the overall results comparable to the 1981–1995 period in Norway. This indicates that in our non-Western population additional, classic, factors are somewhat more involved in HNSCC outcomes. On the other hand, some of the “younger population” trends were recently shown to be changing in the Western populations as well [6,7]. However, data [8] also suggests that the prognostic advantage of HPV is attenuated in older patients.

Current literature also suggests significant geographical variations of HPV involvement in HNSCC. This was recently supported by a study [50] analyzing data from 4 multinational randomized trials, which suggested geographic variability as being important for OPSCC. In the study of Mehanna et al., HPV+ (DNA and p16 together) HNSCC seemed to be of less relevance in Eastern Europe (6%) and Asia (2%) compared to more developed Western countries (37%), where most of current literature derives from [50]. For comparison, in our study, there were only 8 cases where both DNA, RNA and p16 were positive (7%) or 10 cases (8.7%) where only DNA and p16 were positive, suggesting that the data is similar and HPV doesn’t play a major role in HNSCC in this geographical region. Similar data is seen in other socio-economically alike populations as Spain [51], where HPV/p16 positive samples amount to 6% of OPSCC cases and there was no significant survival improvement for HPV/p16 positive cases. Data from geographically closer Italy suggests that HPV driven HNSCC there are also under-represented compared to the rest of Western/Northern Europe. However, survival was positively affected in their HPV driven tumor patients [52], which might also be affected by relatively greater economic development of North Italy region analyzed therein.
Another recent study describes predictors of OPSCC survival in Europe [53]; the analysis was based on 321 OPSCC subset with similar patient characteristics as ours. The study indicated reduced hazard ratio of 0.59 for HPV serology positive patients, whereas, in our study there were no significant differences in survival, which is most likely due to potential behavior differences between Western and non-Western populations.

Our study had several limitations. The first limitation was due to the nature of FFPE samples where the nucleic acid quality is suboptimal, however, this was mitigated by the use of PCR assays suitable both for DNA and RNA amplification from FFPE material. Furthermore, internal control beta-actin amplifications were performed to assess material suitability before HPV amplification. The second limitation was the retrospective nature of the study, where proper documentation was not always available; sometimes detailed follow-up was impossible because the patient visited other hospitals after initial treatment. Therefore, the medical records were supplemented by data (if available) from the Croatian Cancer Registry that on a national level collects relevant information on patient’s cancer irrespective of where the patient was referred, and also contains survival data. The European multicenter study [53] also faced data obstacles to a similar extent (22% missing cancer stage information herein; 16% in their study). Finally, the third limitation was the relatively small size that correlates with the incidence of oropharyngeal cancer in Croatia. However, to put our results in to context, the recent meta-analysis by Albers et al [30] looking at the influence of HPV and p16 patterns on HNSCC patient survival included 25 different studies of which the current study falls roughly in the middle of regarding sample size.

Conclusions

In summary, this study provides the baseline relevant data for treatment of OPSCC patients in Croatia. Eventual policy and treatment decisions in similar regions should take into account the particularities of each population. Other factors like advanced stage, patient age or still highly prevalent smoking and drinking in Croatia might be overshadowing the positive effect of HPV seen in Western populations. Current data indicates that HPV, as a favorable prognostic marker, should not be considered to outweigh other relevant factors in a particular population until other socio-epidemiological changes evident in Western populations are also observed.

Acknowledgments

The authors are obligated to all medical doctors, nurses and administrators who have contributed to the collection of samples analyzed in this study. The authors are especially grateful to Dr. Luka Vučemilo for his fruitful discussions, Mrs. Ljubica Bubanović for her precious information on the study group, Nathaniel Edward Bennett Saidu for proof reading the manuscript and to Mrs. Jasmina Golubić Talić for her expert technical assistance.

Author Contributions

**Conceptualization:** Ivan Sabol, Drago Prgomet, Magdalena Grce.

**Data curation:** Ivan Sabol, Zoran Rakušić, Antonia Jakovčević, Mario Šekerija, Juraj Lukinović, Drago Prgomet.

**Formal analysis:** Ksenija Božinović, Ivan Sabol.

**Funding acquisition:** Magdalena Grce.
Investigation: Ksenija Božinović, Ivan Sabol, Zoran Rakušić, Antonia Jakovčević, Juraj Lukinović.

Methodology: Ksenija Božinović.

Project administration: Magdalena Grce.

Resources: Zoran Rakušić, Antonia Jakovčević, Mario Šekerija, Drago Prgomet, Magdalena Grce.

Supervision: Ivan Sabol, Drago Prgomet, Magdalena Grce.

Writing – original draft: Ksenija Božinović, Ivan Sabol, Magdalena Grce.

Writing – review & editing: Ksenija Božinović, Ivan Sabol, Zoran Rakušić, Antonia Jakovčević, Mario Šekerija, Juraj Lukinović, Drago Prgomet, Magdalena Grce.

References

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet Lond Engl. 2008; 371: 1695–1709. https://doi.org/10.1016/S0140-6736(08)60728-X

2. Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma–similarities and differences among anatomical sites. Am J Cancer Res. 2011; 1: 275. PMID: 21938273

3. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017; 3: 524–548. https://doi.org/10.1001/jamaoncol.2016.5688 PMID: 27918777

4. Croatian National Cancer Registry. Cancer incidence and mortality in Croatia. 2014 [Internet]. Zagreb: Croatian Institute of Public Health; 2016. Report No.: 39. Available: https://www.hzjz.hr/wp-content/uploads/2013/11/Bilten-2014_final.pdf

5. Taberna M, Mena M, Pávón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017; 28: 2386–2398. https://doi.org/10.1093/annonc/mdx304 PMID: 28633362

6. Chaturvedi AK, Zumsteg ZS. A snapshot of the evolving epidemiology of oropharynx cancers. Cancer. 2018; 124: 2893–2896. https://doi.org/10.1002/cncr.31383 PMID: 29710383

7. Windon MJ, D’Souza G, Rettig EM, Westra WH, Zante A van, Wang SJ, et al. Increasing prevalence of human papillomavirus–positive oropharyngeal cancers among older adults. Cancer. 2018; 124: 2993–2999. https://doi.org/10.1002/cncr.31385 PMID: 29710393

8. Rettig EM, Zaidi M, Faraji F, Eisele DW, El Asmar M, Fung N, et al. Oropharyngeal cancer is no longer a disease of younger patients and the prognostic advantage of Human Papillomavirus is attenuated among older patients: Analysis of the National Cancer Database. Oral Oncol. 2018; 83: 147–153. https://doi.org/10.1016/j.oraloncology.2018.06.013 PMID: 30096771

9. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers. J Natl Cancer Inst. 2008; 100: 407–420. https://doi.org/10.1093/jnci/djn025 PMID: 18334711

10. O’Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012; 48: 1191–1201. https://doi.org/10.1016/j.oraloncology.2012.06.019 PMID: 22841677

11. Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev. 2016; 42: 24–29. https://doi.org/10.1016/j.ctrv.2015.10.009 PMID: 26547133

12. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. J Clin Oncol. 2011; 29: 4294–4301. https://doi.org/10.1200/JCO.2011.36.4596 PMID: 21969503

13. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015; 33: 3235–3242. https://doi.org/10.1200/JCO.2015.61.6995 PMID: 26351338
14. Osazuwa-Peters N, Simpson MC, Massa ST, Adjei Boakye E, Antisdel JL, Varvares MA. 40-year incidence trends for oropharyngeal squamous cell carcinoma in the United States. Oral Oncol. 2017; 74: 90–97. https://doi.org/10.1016/j.oraloncology.2017.09.015 PMID: 29103758

15. Znaor T, Vučernilo L, Kulis T, Znaor A. Incidence and mortality trends of head and neck cancer in Croatia in the period 1988–2008. Acta Otolaryngol (Stockh). 2013; 133: 305–312. https://doi.org/10.3109/00016489.2012.743031 PMID: 23176061

16. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, et al. Prevalence of human papillomavirus in oropharyngeal and non-opharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck. 2013; 35: 747–755. https://doi.org/10.1002/hed.22015 PMID: 22267298

17. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res Off J Am Assoc Cancer Res. 2015; 21: 870–881. https://doi.org/10.1158/1078-0432.CCR-14-2481 PMID: 25942084

18. Dok R, Nyufts S. HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies. Cancers. 2016; 8: 41. https://doi.org/10.3390/cancers8040041 PMID: 27043631

19. Marcu LG. Future treatment directions for HPV-associated head and neck cancer based on radiobiological rationale and current clinical evidence. Crit Rev Oncol Hematol. 2016; 103: 27–36. https://doi.org/10.1016/j.critrevonc.2016.05.002 PMID: 27221393

20. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010; 17: 1471–1474. https://doi.org/10.1245/s10434-010-0985-4 PMID: 20180029

21. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliaccio JC, et al. Head and Neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67: 122–137. https://doi.org/10.3322/caac.21389 PMID: 28128948

22. Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J. Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma. Infect Agent Cancer. 2010; 5: 2. https://doi.org/10.1186/1750-9378-5-2 PMID: 20180999

23. Snijders PJ, van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM. The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol. 1990; 71: 173–181. https://doi.org/10.1099/0022-1317-71-1-173 PMID: 2154534

24. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeyer JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048–1056. https://doi.org/10.1016/S1470-2045(10)70230-4 PMID: 20952254

25. Smeets SJ, Hesseling AT, Speel E-JM, Haesevoets A, Snijders PJF, Pawlita M, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer J Int Cancer. 2007; 121: 2465–2472. https://doi.org/10.1002/ijc.22980 PMID: 17680565

26. Prigge E-S, Toth C, Dyckhoff G, Wagner S, Müller F, Wittekindt C, et al. p16(INK4a) /Ki-67 co-expression specifically identifies transformed cells in the head and neck region. Int J Cancer. 2015; 136: 1589–1599. https://doi.org/10.1002/ijc.29130 PMID: 25104331

27. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tań PF, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med. 2010; 363: 24–35. https://doi.org/10.1056/NEJMoa091524 PMID: 2007/s12105-012-0370-7 PMID: 20530316

28. Robinson M, Schache A, Sloan P, Thavaraj S. HPV specific testing: a requirement for oropharyngeal squamous cell carcinoma patients. Head Neck Pathol. 2012; 6 Suppl 1: S83–90. https://doi.org/10.1007/s12105-012-0370-7 PMID: 22782227

29. Seiwort T. Accurate HPV testing: a requirement for precision medicine for head and neck cancer. Ann Oncol Off J Eur Soc Med Oncol. 2013; 24: 2711–2713. https://doi.org/10.1093/annonc/mdt417 PMID: 24170608

30. Albers AE, Qian X, Kaufmann AM, Coordes A. Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci Rep. 2017; 7: 16715. https://doi.org/10.1038/s41598-017-16918-w PMID: 29196639

31. Stephen JK, Divine G, Chen KM, Chitale D, Havard S, Worsham MJ. Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma. Cancer Clin Oncol. 2013; 2: 51–61. https://doi.org/10.5539/cco.v2n1p51 PMID: 23935769

32. Jordan RC, Lingen MW, Perez-Ordonez B, Hs X, Pickard R, Kolder M, et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012; 36: 945–954. https://doi.org/10.1097/PAS.0b013e318253a2d1 PMID: 22743284
33. TCGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015; 517: 576–582. [https://doi.org/10.1038/nature14129 PMID: 25631445]

34. Majchrzak E, Syzbiak B, Wegner A, Pienkowski P, Pazdrowski J, Luczewski L, et al. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol Oncol. 2014; 48: 1–10. [https://doi.org/10.2478/raon-2013-0057 PMID: 24587773]

35. Ramqvist T, Grün N, Dalianis T. Human Papillomavirus and Tonsillar and Base of Tongue Cancer. Viruses. 2015; 7: 1332–1343. [https://doi.org/10.3390/v7031332 PMID: 25803099]

36. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119: 2620–2623. [https://doi.org/10.1002/ijc.22177 PMID: 16991119]

37. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud N, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009; 125: 362–366. [https://doi.org/10.1002/ijc.23439 PMID: 19330833]

38. Padjen I, Dabić M, Glivić M, Biolož B, Biolož B, et al. The analysis of tobacco consumption in Croatia—are we successfully facing the epidemic? Cent Eur J Public Health. 2012; 20: 5–10. PMID: 22571009

39. Commar A, Prasad VK, Tursan d’Espaignet E, Wolfenden L, World Health Organization. WHO global report on trends in prevalence of tobacco smoking 2000–2025. 2018.

40. Hafkamp HC, Manni JJ, Haesevoets A, Voogd AC, Schildcruts M, Bot FJ, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer. 2008; 122: 2656–2664. [https://doi.org/10.1002/ijc.23458 PMID: 18360824]

41. Descamps G, Karaca Y, Lechien JR, Kindt N, Decaestecker C, Remmelink M, et al. Classical risk factors, but not HPV status, predict survival after chemoradiation in advanced head and neck cancer patients. J Cancer Res Clin Oncol. 2016; 142: 2185–2196. [https://doi.org/10.1007/s00432-016-2203-7 PMID: 27370781]

42. Anantharaman D, Muller DC, Lagiou P, Ahrens W, Holcstová I, Merletti F, et al. Combined effects of smoking and HPV16 in oropharyngeal cancer. Int J Epidemiol. 2016; 45: 752–761. [https://doi.org/10.1093/ije/dyw069 PMID: 2719530]

43. Berthiller J, Straif K, Agudo A, Ahrens W, Bezerra Dos Santos A, Boccia S, et al. Low frequency of cigarette smoking and the risk of head and neck cancer in the INHANCE consortium pooled analysis. Int J Epidemiol. 2016; 45: 835–845. [https://doi.org/10.1093/ije/dyv146 PMID: 26228584]

44. Siroglavč K-J, Polić Vižintin M, Tripković I, Šekerija M, Kukuljić S. Trends in incidence of lung cancer in Croatia from 2001 to 2013: gender and regional differences. Croat Med J. 2017; 58: 358–363. [https://doi.org/10.3325/cmj.2017.58.358 PMID: 29094814]

45. Marron M, Boffetta P, Moller H, Ahrens W, Pohlabeln H, Benhamou S, et al. Risk of upper aerodigestive tract cancer and type of alcoholic beverage: a European multicenter case-control study. Eur J Epidemiol. 2012; 27: 499–517. [https://doi.org/10.1007/s10654-012-9699-1 PMID: 22692594]

46. World Health Organization, Management of Substance Abuse Team, World Health Organization. Global status report on alcohol and health 2018. [Internet]. 2018. Available: http://www.who.int/substance_abuse/publications/global_alcohol_report/en/

47. Rettig E, Kiess AP, Fahkry C. The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev Anticancer Ther. 2015; 15: 35–49. [https://doi.org/10.1586/14737140.2015.957189 PMID: 22571009]

48. Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HCW, et al. Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review. Eur J Cancer. 2019; 95: 115–127. [https://doi.org/10.1016/j.ejca.2019.05.026 PMID: 28654785]

49. Nygård M, Aagnes B, Bray F, Møller B, Mork J. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer. 2019 Oct 1; 122: 24–31. [https://doi.org/10.1016/j.ejca.2019.07.011 PMID: 31239521]

50. Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas–Baldwin N, et al. Geographic variation in human papillomavirus–related oropharyngeal cancer: Data from 4 multinational randomized trials. Head Neck. 2016; 38: E1863–E1869. [https://doi.org/10.1002/hed.24336 PMID: 26749143]

51. Rodrigo JP, Heideman DAM, García-Pedrero JM, Fresno MF, Brakenhoff RH, Díaz Molina JP, et al. Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990–2009). Int J Cancer. 2014; 134: 487–492. [https://doi.org/10.1002/ijc.28385 PMID: 23824638]

52. Baboci L, Holzinger D, Boscolo-Rizzo P, Tirelli G, Spinato R, Lupato V, et al. Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Res. 2016; 2: 133–140. [https://doi.org/10.1016/j.pvr.2016.07.002 PMID: 29074172]
53. Anantharaman D, Billot A, Waterboer T, Gheiti T, Abedi-Ardekani B, Lagiou P, et al. Predictors of oropharyngeal cancer survival in Europe. Oral Oncol. 2018; 81: 89–94. https://doi.org/10.1016/j.oraloncology.2018.04.016 PMID: 29884419